Skip to content
Hair Pipeline
enfr
← Back to the pipeline

Olevaprubart (IMG-007)

Olevaprubart (IMG-007) is in Phase 2 for alopecia areata, developed by ImageneBio.

A long-acting anti-OX40 antibody whose effect on alopecia areata scores, in the company's open-label data, was still growing seven months after the last dose.

Phase 2BiologicInjectableImmunomodulator

Monthly digest of verified phase changes. A confirmation link goes out first; unsubscribe is one click on every mail.

Developed by
ImageneBio
Current phase
Phase 2

Tests whether it works, at what dose, in a few hundred people.

Mechanism
Immunomodulator

Retunes the immune system more broadly than a single pathway.

Indications
Alopecia areata
Also known as
IMG-007, IMG007
Last public activity
February 2026
Copy last reviewed
September 2026
Record confidence
High

A research record, not medical advice: being listed here says nothing about whether a treatment works or whether it is right for you. Talk to a dermatologist about your own case.

How it is meant to work

A humanised IgG1 antibody that blocks OX40 on T cells without depleting them, engineered for a long half-life. Amlitelimab, also in this register, targets the ligand side of the same OX40 pair.

Why it matters

In the Phase 2a, 29 adults with at least half the scalp affected were treated open-label at two dose levels, dosed at baseline, week 2 and week 4. On 600 mg the mean SALT score fell 14.3% by week 24 and 21.7% by week 36, about seven and a half months after the last injection, which the company reads as durability; 300 mg did almost nothing. Small, open-label, no placebo arm; results have been posted to the registry. ImageneBio, as Inmagene is now called, said in August 2026 it would start a Phase 2 in alopecia areata before the end of the year, with first data in 2028.

Development history

  1. Phase 1/2

    First Phase 1/2 trial on record: NCT06060977 — A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of IMG-007 in Adult Alopecia Areata Participants

    ClinicalTrials.gov ↗

Registered trials

Pulled automatically from ClinicalTrials.gov. Matching is by name and development code, so occasional gaps are possible — tell us if you spot one.

  • NCT06060977Phase 1/2Completed

    A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of IMG-007 in Adult Alopecia Areata Participants

    Inmagene LLC · n=29 · September 2023

Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first.

Sources

Related programmes

Other programmes in the register with the same mechanism: Immunomodulator.

Cite this page

Hair Pipeline, "Olevaprubart (IMG-007) — development record", hairpipeline.com/pipeline/olevaprubart